KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Liabilities (2016 - 2025)

Travere Therapeutics' Total Liabilities history spans 15 years, with the latest figure at $490.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 8.35% year-over-year to $490.4 million; the TTM value through Dec 2025 reached $490.4 million, down 8.35%, while the annual FY2025 figure was $490.4 million, 8.35% down from the prior year.
  • Total Liabilities reached $490.4 million in Q4 2025 per TVTX's latest filing, up from $465.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $629.7 million in Q4 2022 to a low of $401.4 million in Q1 2021.
  • Average Total Liabilities over 5 years is $541.3 million, with a median of $535.5 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: soared 54.54% in 2022, then dropped 13.54% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $474.5 million in 2021, then surged by 32.71% to $629.7 million in 2022, then dropped by 6.61% to $588.1 million in 2023, then fell by 9.02% to $535.0 million in 2024, then dropped by 8.35% to $490.4 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Total Liabilities are $490.4 million (Q4 2025), $465.0 million (Q3 2025), and $522.6 million (Q2 2025).